Imodium Original

Loperamide Hydrochloride, the active ingredient in Imodium Original, is an antidiarrheal presented as an oral tablet for oral use. It reduces intestinal motility and increases water absorption, helping to control acute and chronic diarrheal episodes in adults and older children. GNH USA supplies Imodium Original as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium Original is an antidiarrheal that acts on the gastrointestinal tract to manage excess stool output. - Acute nonspecific diarrhea: decreases stool frequency and improves consistency. - Chronic diarrhea associated with inflammatory bowel disease: helps maintain symptom control when other therapies are insufficient. - Travelers' diarrhea: provides rapid relief of loose stools during short‑term travel‑related episodes.

Adverse reactions may occur with any antidiarrheal therapy.

Common Side Effects: - Abdominal cramps or discomfort. - Constipation or hard stools. - Nausea or mild vomiting. - Dry mouth. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction. - Toxic megacolon, especially in ulcerative colitis. - Allergic reactions such as rash, pruritus, or angioedema. - Cardiac arrhythmias including QT prolongation at high systemic levels.

Before using Imodium Original, consider the following safety measures. - Assess dehydration: evaluate fluid and electrolyte status prior to therapy. - Avoid use in children under two years: contraindicated due to risk of severe constipation. - Do not exceed recommended dose: higher doses increase risk of serious adverse events. - Use with caution in hepatic impairment: reduced clearance may raise systemic exposure. - Store at room temperature: keep in the original pack, protect from moisture.

Loperamide may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise loperamide plasma levels. - P‑gp inhibitors (e.g., quinidine, verapamil): increase systemic exposure and risk of cardiac effects.

Moderate Interactions (Monitor Closely): - Opioid analgesics: additive central opioid effects may occur. - Anticholinergic agents: may exacerbate constipation. - Other antidiarrheal agents: overlapping mechanisms can lead to excessive slowing of gut motility.